AR080057A1 - Piridinas disustituidas como anticancerigenos - Google Patents
Piridinas disustituidas como anticancerigenosInfo
- Publication number
- AR080057A1 AR080057A1 ARP110100297A ARP110100297A AR080057A1 AR 080057 A1 AR080057 A1 AR 080057A1 AR P110100297 A ARP110100297 A AR P110100297A AR P110100297 A ARP110100297 A AR P110100297A AR 080057 A1 AR080057 A1 AR 080057A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenylene
- lower alkylene
- optionally substituted
- bond
- alkylene
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000006588 heterocycloalkylene group Chemical group 0.000 abstract 2
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composiciones farmacéuticas, uso de los compuestos para preparar medicamentos utiles como antitumorales. Reivindicacion 1: Un compuesto representado por la formula general (1) o una de sus sales; caracterizado porque R1 es fenilo o anillo heterocíclico insaturado, cada uno de los cuales está opcionalmente sustituido con uno o varios sustituyentes; A es alquileno inferior; anillo X es arileno opcionalmente sustituido; E es enlace o alquenileno inferior; la formula estructural parcial (2) de la formula general (1) es heterocicloalquileno opcionalmente sustituido que contiene uno o varios átomos de nitrogeno, uno de los cuales está unido al grupo carbonilo adyacente, en donde dicho heterocicloalquileno contiene opcionalmente otro heteroátomo; G es -NH-G2-, -N(alquil inferior)-G2-, -NH-CH2-G2-, -N(alquil inferior)-CH2-G2- o -CH2-G2-; en donde G2 de dicho G se une con R2; G2-R2 es enlace-R2, fenilen-G3-R2, fenilen-G4-O-R2, fenilen-G5-NH-R2, fenilen-G6-N(alquil inferior)-R2 o quinolindiil-O-R2, en donde el fenileno de dicho fenilen-G3-R2, fenilen-G4-O-R2, fenilen-G5-NH-R2 y fenilen-G6-N(alquil inferior)-R2 está opcionalmente sustituido con uno o varios sustituyentes de una o varias especies seleccionadas del grupo que consisten en halogeno y alquilo inferior; G3-R2 es enlace-R2, -O-alquilen inferior-R2, alquilen inferior-O-alquilen inferior-R2 u -O-alquilen inferior-CO-R2; G4-O- es enlace-O-, alquilen inferior-O-, alquenilen inferior-O-, -O-alquilen inferior-O- o -CO-alquilen inferior-O-; G5 es alquileno inferior; G6 es alquileno inferior; y R2 es arilo o anillo heterocíclico insaturado, cada uno de los cuales está opcionalmente sustituido con uno o varios sustituyentes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29963110P | 2010-01-29 | 2010-01-29 | |
| US35972910P | 2010-06-29 | 2010-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080057A1 true AR080057A1 (es) | 2012-03-07 |
Family
ID=43797869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100297A AR080057A1 (es) | 2010-01-29 | 2011-01-28 | Piridinas disustituidas como anticancerigenos |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8722663B2 (es) |
| EP (1) | EP2528897B9 (es) |
| JP (1) | JP5335932B2 (es) |
| KR (1) | KR101411030B1 (es) |
| CN (1) | CN102791690B (es) |
| AR (1) | AR080057A1 (es) |
| AU (1) | AU2011211306B2 (es) |
| CA (1) | CA2788073A1 (es) |
| CO (1) | CO6561817A2 (es) |
| DK (1) | DK2528897T3 (es) |
| EA (1) | EA026042B1 (es) |
| ES (1) | ES2521016T3 (es) |
| HR (1) | HRP20141190T1 (es) |
| IL (1) | IL221146A (es) |
| MX (1) | MX2012008391A (es) |
| MY (1) | MY160875A (es) |
| NZ (1) | NZ601794A (es) |
| PH (1) | PH12012501532A1 (es) |
| PL (1) | PL2528897T3 (es) |
| PT (1) | PT2528897E (es) |
| RS (1) | RS53705B1 (es) |
| SG (1) | SG182663A1 (es) |
| SI (1) | SI2528897T1 (es) |
| SM (1) | SMT201500007B (es) |
| TW (1) | TWI404713B (es) |
| UA (1) | UA107692C2 (es) |
| WO (1) | WO2011093524A1 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013047223A (ja) * | 2011-07-28 | 2013-03-07 | Otsuka Pharmaceut Co Ltd | 医薬 |
| JP6433974B2 (ja) | 2013-03-14 | 2018-12-05 | トレロ ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法 |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
| EP3036222A2 (en) * | 2013-08-23 | 2016-06-29 | Virginia Commonwealth University | Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EA201792214A1 (ru) | 2015-04-10 | 2018-01-31 | Араксис Фарма Ллк | Соединения замещенного хиназолина |
| JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法 |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3364977A4 (en) | 2015-10-19 | 2019-09-04 | Araxes Pharma LLC | PROCESS FOR SCREENING INHIBITORS OF RAS |
| CA3005089A1 (en) | 2015-11-16 | 2017-05-26 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JP2019529484A (ja) | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤 |
| CN110312711A (zh) | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | 作为ras抑制剂的杂环化合物及其使用方法 |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| JP2020521740A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体 |
| TW201906832A (zh) | 2017-05-25 | 2019-02-16 | 美商亞瑞克西斯製藥公司 | 用於癌症治療之化合物及其使用方法 |
| AU2019247498A1 (en) | 2018-04-05 | 2020-11-26 | Sumitomo Pharma Oncology, Inc. | AXL kinase inhibitors and use of the same |
| AU2019310590A1 (en) | 2018-07-26 | 2021-01-14 | Sumitomo Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| BR112021001709A2 (pt) | 2018-08-01 | 2021-05-04 | Araxes Pharma Llc | compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer |
| CN112812781B (zh) * | 2021-01-21 | 2023-09-29 | 西安瑞联新材料股份有限公司 | 一种基于双哌嗪类苯并噁唑液晶化合物及其制备方法 |
| CN116903587B (zh) * | 2023-06-01 | 2024-03-22 | 三峡大学 | 一种角鲨烯环氧酶抑制剂及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63301880A (ja) * | 1985-09-03 | 1988-12-08 | Otsuka Pharmaceut Co Ltd | ５−フルオロウラシル誘導体 |
| AR015733A1 (es) * | 1998-03-25 | 2001-05-16 | Otsuka Pharma Co Ltd | DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO. |
| US6262088B1 (en) * | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
| JP2001089450A (ja) * | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ピリジン誘導体含有医薬製剤 |
| JP2001089412A (ja) * | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
| JP2002226429A (ja) * | 2001-02-06 | 2002-08-14 | Fuji Photo Film Co Ltd | アクリル酸エステル化合物の製造方法 |
| GB0224917D0 (en) * | 2002-10-25 | 2002-12-04 | Novartis Ag | Organic compounds |
| US8188277B2 (en) | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
| JP5142513B2 (ja) * | 2005-12-05 | 2013-02-13 | 大塚製薬株式会社 | 医薬 |
| CA2630468C (en) | 2005-12-05 | 2015-01-20 | Otsuka Pharmaceutical Co., Ltd. | Medicinal drug |
| UA95978C2 (ru) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
| WO2009005781A1 (en) | 2007-07-02 | 2009-01-08 | Dave Young | System and method for clinical trial investigator meeting delivery and training, including dynamic media enrichment |
| TWI440638B (zh) | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
| DE202009007345U1 (de) * | 2009-05-22 | 2009-09-10 | Schebo (R) . Biotech Ag | Neue Pharmazeutika und Arzneimittelzubereitungen |
-
2011
- 2011-01-28 RS RS20140688A patent/RS53705B1/sr unknown
- 2011-01-28 WO PCT/JP2011/052302 patent/WO2011093524A1/en not_active Ceased
- 2011-01-28 US US13/318,053 patent/US8722663B2/en not_active Expired - Fee Related
- 2011-01-28 PH PH1/2012/501532A patent/PH12012501532A1/en unknown
- 2011-01-28 ES ES11705048.4T patent/ES2521016T3/es active Active
- 2011-01-28 JP JP2011545133A patent/JP5335932B2/ja not_active Expired - Fee Related
- 2011-01-28 CA CA2788073A patent/CA2788073A1/en not_active Abandoned
- 2011-01-28 PL PL11705048T patent/PL2528897T3/pl unknown
- 2011-01-28 SI SI201130359T patent/SI2528897T1/sl unknown
- 2011-01-28 SG SG2012054243A patent/SG182663A1/en unknown
- 2011-01-28 CN CN201180007162.2A patent/CN102791690B/zh not_active Expired - Fee Related
- 2011-01-28 AU AU2011211306A patent/AU2011211306B2/en not_active Ceased
- 2011-01-28 MX MX2012008391A patent/MX2012008391A/es active IP Right Grant
- 2011-01-28 HR HRP20141190AT patent/HRP20141190T1/hr unknown
- 2011-01-28 UA UAA201209216A patent/UA107692C2/uk unknown
- 2011-01-28 TW TW100103410A patent/TWI404713B/zh not_active IP Right Cessation
- 2011-01-28 AR ARP110100297A patent/AR080057A1/es unknown
- 2011-01-28 KR KR1020117025212A patent/KR101411030B1/ko not_active Expired - Fee Related
- 2011-01-28 PT PT117050484T patent/PT2528897E/pt unknown
- 2011-01-28 EA EA201290720A patent/EA026042B1/ru not_active IP Right Cessation
- 2011-01-28 MY MYPI2012003367A patent/MY160875A/en unknown
- 2011-01-28 NZ NZ601794A patent/NZ601794A/en not_active IP Right Cessation
- 2011-01-28 DK DK11705048.4T patent/DK2528897T3/en active
- 2011-01-28 EP EP11705048.4A patent/EP2528897B9/en active Active
-
2012
- 2012-07-19 CO CO12121461A patent/CO6561817A2/es unknown
- 2012-07-26 IL IL221146A patent/IL221146A/en not_active IP Right Cessation
-
2015
- 2015-01-09 SM SM201500007T patent/SMT201500007B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080057A1 (es) | Piridinas disustituidas como anticancerigenos | |
| AR085283A1 (es) | Antagonistas de hepcidina a base de sulfonaminoquinolina | |
| AR090868A1 (es) | Composiciones plaguicidas y procesos relacionados con ellas | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
| MX347860B (es) | Lípidos y composiciones novedosos para el suministro de agentes terapéuticos. | |
| MX2012008533A (es) | Naftiridinas sustituidas y su uso como inhibidores de syk quinasa. | |
| BR112014010644A2 (pt) | novos derivados de aril-quinolina | |
| AR086829A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| PE20141552A1 (es) | Composiciones farmaceuticas | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR093832A1 (es) | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO | |
| AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| CR20140217A (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii | |
| BR112013018732A2 (pt) | novos derivados de amida de aril-benzocicloalquila | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR089753A1 (es) | Derivados de amida heterociclicos como antagonistas del receptor p2x7 | |
| PE20141940A1 (es) | Compuestos triciclicos, composiciones que los comprenden y usos de los mismos | |
| UY33655A (es) | Co-cristales y sales de inhibidores de ccr30 | |
| AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
| AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
| AR101317A1 (es) | Moléculas que poseen ciertas utilidades plaguicidas, intermediarios, composiciones y procesos relacionados con dichas moléculas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |